ARC and cancer: Different cancer cell lines with varied expression levels of FRα, including SKOV3 (FRα+), A2780 (FRα+), CAKI-1 (FRα-), and A549 (FRα-) (Fig. 3C), were used to evaluate binding specificity of FA-ARC Exos.